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ABSTRACT 
 
INTRODUCTION: Autoimmune rheumatic diseases such as systemic lupus 
erythematosus (SLE), antiphospholipid syndrome (APS) and Sjögren’s syndrome (SS) 
are part of a clinical spectrum which affects women in child-bearing age, affecting 
pregnancy and neonatal outcome. Preterm birth, foetal growth restriction (FGR) and 
neonatal lupus (NL) – cardiac, cutaneous, haematological, hepatic and, more rarely, 
pulmonary manifestations – have been described.  
 
OBJECTIVE: This study aims to evaluate pregnancy outcome focusing on preterm 
birth and FGR of rheumatologic immune-mediated diseases in the mother and on 
neonatal manifestations in their babies in “Centro Hospitalar São João”, Porto, Portugal, 
between 2010 and 2015. 
 
METHODS: A retrospective longitudinal study was performed including pregnant 
women with immune-mediated rheumatic diseases seen by a multidisciplinary team for 
pregnancy surveillance of women with autoimmune diseases. Data was collected 
through consultation of clinical files. Pregnancy outcome such as preterm birth and 
FGR and babies with and without NL were compared between themselves using Mann-
Whitney, chi-square and Fisher tests. Significance level was set at p<0.05. 
 
RESULTS: 140 women had 147 gestations, including 4 twin pregnancies, and 
delivered 142 live born babies; 7 (4.6%) abortions and 2 (1.3%) stillbirths occurred. 
During gestation, 54 (35.8%) foetuses’ mothers had SLE, 41 had (27.2%) APS, 17 
(11.3%) had SS, 17 (11.3%) had RA, 11 (7.3%) had Behçet’s disease, 8 had (5.3%) 
mixed connective tissue disorders, 4 had (2.6%) systemic sclerosis, and 16 (10.6%) had 
other immune-mediated diseases. Thirty-five (23.2%) had anti-SSA/La antibodies and 
18 (11.9%) had anti-SSB antibodies. Nineteen (13.2%) foetuses had FGR during 
gestation and 28 (19.7%) were delivered before term. Six (4.2%) neonates were born 
with NL and 1 (0.7%) died in utero with a complete heart block (CHB). Out of these 7 
babies with NL, 5 (71.4%) had cardiac, 2 had (28.6%) cutaneous, 1 (14.3%) had 
hepatic, 2 (28.6%) had haematological and 1 (14.3%) had pulmonary manifestations. 
Preterm birth and FGR occurred less frequently among women who had a 
preconception appointment (0.0% vs. 27.2%; p=0.004 and 7.1% vs. 28.1%; p=0.013, 
respectively). FGR occurred less among women with rheumatic diseases in remission at 
conception (7.1% vs. 23.7% p=0.038). NL manifestations occurred more frequently in 
mothers with SS (57.1% vs. 8.8%; p=0.003) and FGR (42.9% vs. 11.7%; p=0.049). 
 
CONCLUSION: Our study proved a link between immune-mediated rheumatic 
diseases and specific pregnancy outcome like preterm birth, FGR and NL. These may 
be altered if women attend a preconception appointment and plan pregnancy, 
conceiving at a remission period of the disease. FGR associated with anti-SSa/Ro and 
anti-SSb/La antibodies may be considered a predicting factor for NL. Multidisciplinary 
pre-pregnancy counselling as well as rheumatologic and obstetric surveillance should be 
recommended to all women with immune-mediated rheumatic diseases. 
 
KEYWORDS: preterm birth, fetal growth restriction, neonatal lupus, pregnancy 
outcome, neonatal outcome, preconception 
 
 
1. Introduction 
 
Autoimmune rheumatic diseases such as systemic lupus erythematosus (SLE), anti-
phospholipid syndrome (APS), rheumatoid arthritis (RA) and Sjögren’s syndrome (SS) 
are part of a clinical spectrum which affects women in child-bearing age. SLE, APS and 
RA have been more intensively studied regarding pregnancy and neonatal impact as 
they are the most frequent immune-mediated diseases to occur during this period.  
 
When pregnancy co-exists with this set of pathologies, severe maternal-foetal 
complications may arise, not only derived from the disease itself, but also as a 
consequence of administered drugs, such as anti-inflammatory, immunosuppressive and 
disease-modifying drugs [1] and incorrect conception planning. SLE has been shown to 
increase the risk of recurrent pregnancy loss, foetal loss, preterm birth, preeclampsia 
and foetal growth restriction (FGR) [2-5]. APS, for instance, is associated with an 
increased prevalence of recurrent spontaneous pregnancy loss and FGR, possibly due to 
thrombosis of placental vessels [6, 7]. RA usually presents good pregnancy outcome 
with less symptomatology and need of analgesic drugs [8]. Smaller birthweight has also 
been reported in primary SS [9]. Nonetheless, if conceiving occurs during a period of 
remission, these complications occur less frequently [2, 4]. The remaining diseases lack 
evidence regarding maternal-foetal consequences.  
 
Autoimmune diseases that are seropositive for specific antibodies during pregnancy 
may also lead to transplacental transfer of maternal IgG antibodies to the foetal 
circulation, originating neonatal autoimmune diseases [10]. The most common is 
neonatal lupus (NL) that usually expresses itself as complete heart block (CHB) and/or 
cutaneous rash, but may also express as hepatobiliary disease and/or cytopenia [11].  It 
can occur among mothers with anti-SSa/Ro and anti-SSb/La antibodies, which are more 
frequent in SLE, APS and SS, but may also be present in other connective tissue 
disorders [12]. Environmental and foetal genetic factors, namely B-cell, complement or 
interferon (IFN) activation and inflammation may also contribute to the pathogenesis of 
the disease [9, 13].  
 
Cutaneous NL usually presents at 6 weeks of life or later [14] and tends to dissipate at 
around 17 weeks, when maternal antibodies disappear from the foetal circulation [15]. 
Skin lesions consist of erythematous annular and scalous plaques with a central 
clearing. They are frequently found on the face and scalp and less frequently on the 
arms, legs and trunk [13, 16]. Photosensitivity is also a frequent finding, as it is 
considered a trigger for cutaneous lesions, although it is difficult to evaluate [15]. Even 
though these are transient, atrophic and scarring lesions, telangiectasia, 
hypopigmentation and alopecia may persist [17].   
 
Anti-SSA/Ro and anti-SSB/La antibodies accumulate around the AV node conduction 
system [18], promoting inflammation, scarring and fibrosis [19]. This manifestation, the 
second most common after cutaneous NL, can presents itself as first-, second-, or third-
degree (complete) heart block and may be diagnosed in utero or postnatally [14]. 
Around 70% of affected children require pacemaker [20]. Neonates may also develop 
diffuse cardiomyopathies [21], endocardial fibroelastosis [22], prolonged QT interval 
[23] and sinus bradycardia [24].  
 
Regarding liver involvement, NL may either present as neonatal haemochromatosis, in 
which liver failure occurs in utero or after birth, or as cholestasis with conjugated 
hyperbilirubinemia and minimal or transient transaminase elevations a few weeks after 
birth [13, 16]. Other studies also report liver enlargement [25, 26]. 
 
Concerning haematological complications, research has shown that some blood cells 
contain a Ro cross-reactive protein [27]. Although they may not be present at birth, they 
may develop over time. Clinical manifestations include self-limiting mild anaemia and 
thrombocytopenia, which resolve in 2 to 3 months [28]. 
 
This study aims to evaluate pregnancy outcome focusing on preterm birth and FGR of 
rheumatologic immune-mediated diseases in the mother and on neonatal manifestations 
in their babies in “Centro Hospitalar São João”, Porto, Portugal, between 2010 and 
2015. Maternal outcome as hypertensive disorders of pregnancy and the occurrence of 
lupus flares were not considered for the purpose of this study. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2. Materials and Methods  
 
A retrospective longitudinal study was performed. 
 
2.1 Patients 
 
We included pregnant women with the following immune-mediated rheumatic diseases: 
SLE, SS, RA, APS, Behçet’s disease, systemic sclerosis, polymyositis/ 
dermatomyositis, mixed connective tissue disorders, reactive, psoriatic and juvenile 
arthritis, vasculitis and spondylitis that were seen by a multidisciplinary team for 
autoimmune diseases during pregnancy between January 2010 and December 2015. 
This multidisciplinary team consists of a consultant obstetrician and a senior internist. 
Women who are pregnant are referred to this group by dermatology, internal medicine, 
rheumatology and nephrology. 
  
All gestations of women seen at a first appointment, who had a definite diagnosis at the 
time of pregnancy and had their baby in “Centro Hospitalar São João” were included. 
Time-separated gestations of the same woman during our period of study were also 
considered separate. We therefore included 140 women who had a total of 147 
gestations and delivered 151 babies; 4 twin pregnancies were included.  
 
We excluded women who only had preconception appointment but did not subsequently 
become pregnant, women who did not have a definite autoimmune rheumatic diagnosis 
and gestations that were lost in follow-up. 
 
2.2 Clinical data 
 
Clinical and demographic data as well as pregnancy and neonatal outcome were 
collected through consultation of clinical files and the obstetrics surveillance software 
ObsCareâ. We consulted relevant demographic data from mothers and their babies, 
occurrences of the present gestation – therapeutic drugs, social habits, autoantibody 
profile, gestational age at birth and weight at delivery. Preterm birth was considered 
birth before the 37th week of gestation (≤36+6 weeks) and FGR as the estimated foetal 
weight <P5 for gestational age at ultrasound as defined in the department of 
Gynaecology/ Obstetrics of this hospital. Other relevant details, background and 
neonatal manifestations were also consulted. This research project was approved by the 
local ethics committee.  
 
2.2.1. Statistical analysis 
 
Statistical analysis was performed using IBM SPSS statistics 24.0. Patients with and 
without NL were compared using Mann-Whitney, chi-square and Fisher tests. Factors 
associated with pregnancy outcome were studied using the same tests. Significance 
level was set as p<0.05.  
 
 
 
 
 
 
3. Results 
 
3.1. Descriptive and demographic analysis 
 
During the period of study, 140 women with a mean age of 32,5 ± 4,4 years had 147 
gestations and delivered 142 babies; 7 (4.6%) gestations ended as abortions and 2 
(1.3%) resulted in stillbirths. Four women had twin pregnancies. Fifty-four (35.8%) 
women had SLE, 41 had APS (27.2%), 17 (11.3%) had SS, 17 (11.3%) had RA, 11 
(7.3%) had Behçet’s disease, 8 (5.3%) had mixed connective tissue diseases, 4 (2.6%) 
had systemic sclerosis, 0 (0.0%) had polymyositis/ dermatomyositis, and 16 (10,6%) 
had other immune-mediated diseases described in section 2.1. Thirty-five (23.2%) 
babies were exposed to anti-SSA/La antibodies during pregnancy and 18 (11.9%) to 
anti-SSB/Ro antibodies. Thirty-six (23.8%) of the gestations were seen at a 
preconception appointment and 29 (19.2%) were in a period of remission at the time of 
conception. For further demographic and gestation details, please refer to table 1. 
 
The mean gestational age of birth was 37+4 ± 1+6 weeks. Eighty (53.0%) babies were 
born male. The mean length was 47.5 ± 3.5 cm (lowest: 28.0cm; highest: 52.5 cm), the 
mean weight was 2813.0 ± 533.4 g (lowest: 555.0g; highest: 4140.0g) and the mean 
head circumference was 33.5 ± 1.9 cm (lowest: 21.5cm; highest: 38.0cm). Twenty-eight 
(19.7%) babies were born preterm and 25 (17.6%) were admitted in the neonatal 
intensive care unit (NICU). A total of 7 (4.6%) babies had NL; 1 (0.7%) of them died in 
utero on week 33+4. Concerning immunological profile, apart from anti-SSa and anti-
SSb antibodies, 2 (1.4%) babies were ANA positive, 1 (0.7%) was anti-dsDNA positive 
and 1 (0.7%) was IgM/IgG positive. For further details regarding demographics and 
neonatal manifestations, please refer to table 2. 
 
3.2. Pregnancy outcome 
 
FGR and preterm birth occurred less frequently among mothers who were seen at a 
preconception appointment (0.0% vs. 27.2%; p=0.004 and 7.1% vs. 28.1%; p=0.013, 
respectively). Babies with FGR were more frequently admitted in the NICU (52.6% vs. 
12.0%; p<0.001). Preterm birth occurred less frequently among mothers who were in 
remission period of the disease at the time of conception (7.1% vs. 23.7%; p=0.038). 
Please refer to table 3 for further details regarding FGR and preterm birth. 
 
3.3. Neonatal outcome 
 
Babies with NL were more frequently growth restricted (42.9% vs. 11.7%; p=0.049) 
and were admitted in the NICU more often (71.4% vs. 14.6%; p=0.002). Concerning 
immunological profile in babies with NL, apart from anti-SSa/Ro and anti-SSb/La, 
some antibodies were seen more frequently: anti-DNAds (14.3% vs. 0.0%; p=0.046), 
anti-ß2GP (14.3% vs. 0.0%; p=0.046) and ANA’s (28.6% vs. 0.0%; p=0.002). Other 
relevant details regarding NL may be found in table 4.  
 
 
 
 
 
 
 
4. Discussion 
 
Women with immune-mediated rheumatic diseases are indeed more vulnerable to poor 
pregnancy and neonatal outcome. As Chen et al concluded, infants are at increased risk 
of preterm birth and admission in the NICU [29]. For instance, hypertensive 
complications in SLE have been shown to increase the risk of preterm birth, FGR and 
foetal loss [30, 31].  Our study was not aimed at evaluating hypertensive complications; 
however, it does prove the association between FGR and preterm birth and factors 
associated with autoimmune diseases. 
 
Given that a considerable number of women must maintain their normal glucocorticoid 
intake during pregnancy for autoimmune disease control (53.6%), they become exposed 
to a greater risk of preterm birth and FGR. Furthermore, even though no association was 
found between autoimmune rheumatic diseases and gestational diabetes, the latter 
increases the probability of FGR. 
 
Statistical significance was found between FGR and babies who were born before term. 
Even though literature provides a link between autoimmune rheumatic diseases and 
FGR [6, 32, 33], this study failed to show this association.  
 
Women who had preterm births visited the doctor less frequently for pre-pregnancy 
counselling, possibly leading to conceiving in periods of active disease due to lack of 
compliance, whereas they should conceive in periods of remission, as reinforced by this 
study. 
 
Similar to the statistically significant results for preterm birth, none of the women 
whose babies developed FGR were seen at a preconception appointment, even though 
no association was found between this neonatal outcome and women who conceived in 
a remission period of the disease. Regarding autoantibody profile, no statistically 
significant association was found between the antibodies listed in table 1 and the 
aforementioned pregnancy outcome.  
 
Considering that only mothers with positive anti-SSA/Ro and anti-SSb/La antibodies 
may have babies with NL, it is noteworthy that out of 35 (23.1%) gestations positive for 
these antibodies, 7 (20.0%) babies developed the disease. Literature is consensual when 
describing the incidence of neonatal lupus in the offspring of mothers with anti-
SSA/SSB antibodies, which stands between 1-3% [20, 34, 35] but may reach >20% if 
the mother has previously delivered a child with CHB before [36]. According to our 
study, recurrence occurred in 33% of the cases, although the sample is not significant 
and further conclusions cannot be made. 
 
Moreover, in accordance to what has been previously reported, transplacental passage 
of antibodies to the foetus does not always occur, indicating that environmental factors 
may interfere; nonetheless, these remain unknown and future research should address 
this matter. In our tertiary care facility, it is protocol to screen for anti-SSa/Ro and anti-
SSb/La antibodies in babies whose mothers test positive during pregnancy. None of the 
babies, whose mothers were positive for anti-SSa and anti-SSb antibodies during 
pregnancy, but who did not develop NL, were positive for these antibodies, indicating 
that their passage occurs during gestation and excluding the possibility that babies may 
be asymptomatic carriers. It is also worthy of mention that one of the cases of NL 
occurred in a baby that was born from a twin gestation. Despite both being exposed to 
the same environment, only one of the twins received the antibodies and developed NL. 
This case might be interesting for future studies. 
 
Although many autoimmune diseases may present with anti-SSa/Ro and anti-SSb/La 
antibodies, we only found an association with SS. Neither SLE or APS presented a 
significant association.  
 
The fact that babies with NL were born smaller, with lower Apgar scores at minute 10 
and with a higher admission rate in the NICU might be explained by the fact that 5 of 
the 7 cases of NL had CHB, which indicates poorer birth outcome. Despite the lack of 
association with immunological profile or pregnancy events, one of the babies was born 
with cardiac, haematological, hepatic and pulmonary manifestations. Along with aseptic 
meningitis, myelopathy, lymphadenopathy and chondrodysplasia punctata, lupic 
pneumonitis is a very rare manifestation. Their underlying mechanism has so far not 
been found [37, 38].  
 
What the authors did find interesting was the association of other autoantibodies like 
anti-dsDNA, anti-ß2GP and ANA’s with NL. No data is found in literature regarding 
this association and unfortunately our sample is too small to allow for a definite 
conclusion. Further research should focus on the co-immunological manifestation of 
anti-SSa/Ro and anti-SSb/La antibodies with either ANA’s, anti-ß2GP and anti-dsDNA 
antibodies to determine their influence on NL expression. 
 
4.1. Sources of error 
 
The main drawback of this study lies on its retrospective nature. Furthermore, due to the 
specialized counselling in pregnancy-related autoimmune diseases that our 
multidisciplinary team offers, subjects from this study do not represent the general 
population and therefore constitute a selection bias with overestimation of results.  
 
4.2. Sources of improvement 
 
The multidisciplinary team for autoimmune diseases in pregnancy was established in 
April 2009 which impeded this study from analysing a larger sample. This study should 
be run in roughly 10 years’ time to do so. Furthermore, this study should be carried out 
as a multicentre analysis to eliminate result overestimation. Studies should also compare 
tertiary hospitals with and without a multidisciplinary team for immune-mediated 
diseases in pregnancy to determine differences in approach leading to different possible 
outcome.  
 
 
 
 
 
 
 
5. Conclusions 
Our study proved that: 
1. Multidisciplinary pre-pregnancy counselling as well as rheumatologic and 
obstetric surveillance should be recommended to all women with immune-
mediated rheumatic diseases. During the preconception appointment, women 
should be advised not to conceive while in an active period of disease. 
Conceiving during this period undoubtedly increases glucocorticoid intake 
during pregnancy and consequently the risk of preterm birth, FGR and 
admission in the NICU, thus increasing hospital stay, costs and exposure to 
multi-resistant pathogens. Careful surveillance during pregnancy also leads to a 
better control of gestational diabetes, hence decreasing the risk of FGR.  
 
2. Mothers with previous children with the disease should be carefully advised 
when planning a future pregnancy given the high risk of recurrence.  
 
3. According to the results, FGR associated with anti-SSa/Ro and anti-SSb/La may 
be considered a predicting factor for NL. Babies whose mothers carry the 
antibodies and have FGR during pregnancy should therefore be more 
prominently studied.  
 
4. Besides anti-SSa and anti-SSB, there is an association between NL and ANA’s, 
anti-ß2GP and anti-dsDNA antibodies. Further research should focus on the 
influence of immunological profile in the expression of NL. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Highlights 
 
1. FGR associated with anti-SSa and -SSb antibodies may be predictive factor of 
NL. 
2. There is an association between NL and ANA’s, anti-ß2GP and anti-dsDNA 
antibodies. 
3. Multidisciplinary pre-pregnancy counselling should be recommended. 
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Table 1: Demographic, clinical and immunological characteristics of mothers. 
 
Mother characteristics  
Age at first appointment, mean ± SD (years) 32.5 ± 4.4 
BMI at first appointment, mean ± SD (kg/m2) 26.2 ± 5.4 
Presence of previous miscarriages, n (%) 54 (35.8%) 
Years of disease evolution, mean ± SD 6.0 ± 2.9 
Immune-mediated rheumatic diseases, n (%) 
Systemic lupus erythematosus 54 (35.8%) 
Anti-phospholipid syndrome 41 (27.2%) 
Sjörgen’s syndrome 17 (11.3%) 
Rheumatoid arthritis 17 (11.3%) 
Behçet’s disease 11 (7.3%) 
Systemic sclerosis 4 (2.6%) 
Polyomiositis/ dermatomyositis 0 (0.0%) 
Mixed connective tissue diseases 8 (5.3%) 
Other autoimmune diseases 16 (10.6%) 
Immunological manifestations during pregnancy, n (%) 
Anti-dsDNA positive 22 (14.6%) 
Anti-SSA/Ro positive 35 (23.2%) 
Anti-SSB/La positive 18 (11.9%) 
Anti-U1RNP positive 6 (4.0%) 
Lupus anticoagulant positive 16 (10.6%) 
IgG/IgM anticardiolipin positive 35 (23.2%) 
IgM/IgG anti-ß2GP positive 28 (18.6%) 
Drug administration during pregnancy, n (%) 
Glucocorticoids 81 (53.6%) 
NSAID’s 9 (6.0%) 
Immunosuppressive drugs 9 (6.0%) 
Pregnancy outcome, n (%) 
Gestational diabetes 7 (4.6%) 
Gestational hypertension 5 (3.3%) 
FGR 19 (13.2%) 
Lupic flare 10 (6.6%) 
Miscarriage 9 (6.0%) 
Other relevant details, n (%) 
Pre-conception appointment 36 (23.8%) 
Disease in remission at time of conception 29 (19.2%) 
Mothers with previous children with AV 
blocks 
3 (2.1%) 
BMI: body mass index; AV: atrioventricular 
 
Table 2: Demographic, clinical and immunological characteristics of babies. 
 
Neonatal characteristics  
Birth  
Gestational age, mean ± SD (weeks+days) 37+6 ± 1+6 
Preterm birth, n (%) 28 (19.7%) 
Male gender, n (%) 80 (56.3%) 
Apgar 1’, median ± SD 9 
Apgar 10’, median ± SD  10 
Admission in the NICU, n (%) 25 (17.6%) 
Foetal anthropometry  
Length, mean ± SD (cm) 47.5 ± 3.5 
Weight, mean ± SD (g) 2831.0 ± 533.4 
Head circumference, mean ± SD (cm) 33.5 ± 1.9 
Neonatal manifestations, n (%) 
NL 7 (4.9%) 
Cardiac manifestations 5 (71.4%) 
Type I AV block 1 (20.0%) 
Type II AV block 1 (20.0%) 
Complete AV block 4 (80.0%) 
Need for pacemaker 3 (60.0%) 
Cutaneous manifestations 2 (28.6%) 
Persistence after 6 months 0 (0.0%) 
Persistence of atrophic and/ or 
scarring injuries 
1 (50.0%) 
Haematological manifestations 2 (28.6%) 
Hepatic manifestations 1 (0.0%) 
Pulmonary complications 1 (0.7%) 
Immunological manifestations, n (%) 
ANA positive 2 (1.4%) 
Anti-dsDNA positive 1 (0.7%) 
Anti-SSA/Ro positive 5 (3.5%) 
Anti-SSB/La positive 3 (2.1%) 
Positive clinical features of neonatal lupus 
with lack of immunological information 
1 (0.7%) 
IgM/IgG anti-ß2GP positive 1 (0.7%) 
FGR: intrauterine growth restriction; AV: atrioventricular; NICU: neonatal intensive care 
unit; NL: neonatal lupus 
 
 
 
 
 
 
 
Table 3: Pregnancy outcome of patients. 
	
 FGR n=19 
aFGR 
n=125 p 
Gestation, n (%)    
Gestational diabetes 3 (15.8%) 3 (2.4%) 0.030* 
Preconception appointment 0 (0.0%) 34 (27.2%) 0.004* 
Disease in remission at time of conception 4 (21.1%) 25 (20.0%) 0.561 
Systemic lupus erythematosus 6 (31.6%) 47 (37.6%) 0.407 
Sjögren’s syndrome 3 (15.8%) 13 (10.4%) 0.355 
Anti-phospholipid syndrome 8 (42.1%) 29 (23.2%) 0.074 
Birth    
Preterm birth, n (%) 7 (36.8%) 21 (16.8%) 0.046* 
Admission in the NICU, n (%) 10 (52.6%) 15 (12.0%) <0.001* 
Apgar 1´, median 8.0 9.0 <0.001* 
Apgar 10´, median 9.0 10.0 <0.001* 
Foetal anthropometry, median    
Length at birth (cm) 45.0 48.0 <0.001* 
Weight at birth (g) 2195.0 2930.0 <0.001* 
Head circumference (cm) 32.0 33.5 0.001* 
 
Preterm 
birth 
n=28 
aPreterm 
birth 
n=114 
p 
Gestation, n (%)    
Babies born of twin pregnancies 6 (21.4%) 2 (1.8%) 0.001* 
FGR 7 (25.0%) 10 (8.8%) 0.026* 
Glucocorticoid administration 22 (78.6%) 55 (48.2%) 0.003* 
Preconception appointment 2 (7.1%) 32 (28.1%) 0.013* 
Disease in remission at time of conception 2 (7.1%) 27 (23.7%) 0.038* 
Systemic lupus erythematosus 10 (35.7%) 43 (37.7%) 0.513 
Sjögren’s syndrome 1 (3.6%) 14 (12.3%) 0.158 
Anti-phospholipid syndrome 9 (32.1%) 27 (23.7%) 0.244 
Birth    
Apgar 1´, median 8.0 9.0 0.055 
Apgar 10´, median 9.0 10.0 <0.001* 
Admission in the NICU, n (%) 16 (57.1%) 9 (7.9%) <0.001* 
Foetal anthropometry, median    
Length at birth (cm) 45.0 49.0 <0.001* 
Weight at birth (g) 2280.0 2962.5 <0.001* 
Head circumference (cm) 32.5 33.0 0.007* 
FGR: intrauterine growth restriction; aFGR: not born with FGR; NICU: neonatal 
intensive care unit; aPreterm birth: not born preterm. *: statistically significant result 
 
 
 
 
Table 4: Neonatal manifestations of patients 
	
 NL n=7 
aNL 
n=137 p 
Gestation, n (%)    
FGR 3 (42.9%) 16 (11.7%) 0.049* 
Systemic lupus erythematosus 4 (57.1%) 49 (35.8%) 0.226 
Sjögren’s syndrome 4 (57.1%) 12 (8.8%) 0.003* 
Anti-phospholipid syndrome 0 (0.0%) 37 (27.0%) 0.119 
Immunological manifestations during pregnancy, n (%)  
Anti-SSa/Ro positive 7 (100.0%) 27 (19.7%) <0.001* 
Anti-SSb/La positive 5 (71.4%) 13 (9.5%) <0.001* 
Birth    
Admission in the NICU, n (%) 5 (71.4%) 20 (14.6%) 0.002* 
Apgar 10´, median 9.0 10.0 0.022* 
Foetal anthropometry, median    
Length at birth (cm) 45.5 48.0 0.004* 
Weight at birth (g) 2665.0 2890.0 0.062 
Head circumference at birth (cm) 33.0 33.0 0.569 
Neonatal immunological manifestations, n (%)   
Anti-SSa/Ro positive 5 (71.4%) 0 (0.0%) <0.001* 
Anti-SSb/La positive 3 (42.9%) 0 (0.0%) <0.001* 
Anti-dsDNA positive 1 (14.3%) 0 (0.0%) 0.046* 
Anti-ß2GP positive 1 (14.3%) 0 (0.0%) 0.046* 
ANA positive 2 (28.6%) 0 (0.0%) 0.002* 
NL: neonatal lupus; aNL: not born with neonatal lupus; Anti-: antibody; NICU: neonatal 
intensive care unit. *: statistically significant result 
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Abstract
A concise and factual abstract is required. The abstract should state briefly the purpose of the
research, the principal results and major conclusions. An abstract is often presented separately from
the article, so it must be able to stand alone. For this reason, References should be avoided, but if
essential, then cite the author(s) and year(s). Also, non-standard or uncommon abbreviations should
be avoided, but if essential they must be defined at their first mention in the abstract itself.
Graphical abstract
Although a graphical abstract is optional, its use is encouraged as it draws more attention to the online
article. The graphical abstract should summarize the contents of the article in a concise, pictorial form
designed to capture the attention of a wide readership. Graphical abstracts should be submitted as a
separate file in the online submission system. Image size: Please provide an image with a minimum
of 531 × 1328 pixels (h × w) or proportionally more. The image should be readable at a size of 5 ×
13 cm using a regular screen resolution of 96 dpi. Preferred file types: TIFF, EPS, PDF or MS Office
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Authors can make use of Elsevier's Illustration and Enhancement service to ensure the best
presentation of their images and in accordance with all technical requirements: Illustration Service.
Highlights
Highlights are mandatory for this journal. They consist of a short collection of bullet points that
convey the core findings of the article and should be submitted in a separate editable file in the
online submission system. Please use 'Highlights' in the file name and include 3 to 5 bullet points
(maximum 85 characters, including spaces, per bullet point). You can view example Highlights on
our information site.
Keywords
Immediately after the abstract, provide a maximum of 6 keywords, using American spelling and
avoiding general and plural terms and multiple concepts (avoid, for example, 'and', 'of'). Be sparing
with abbreviations: only abbreviations firmly established in the field may be eligible. These keywords
will be used for indexing purposes.
Abreviations
Define abbreviations that are not standard in this field at their first occurrence in the article in the
abstract and also in the main text after it. Ensure consistency of abbreviations throughout the article.
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use fonts that look similar.
• Number the illustrations according to their sequence in the text.
• Use a logical naming convention for your artwork files.
• Provide captions to illustrations separately.
• Size the illustrations close to the desired dimensions of the published version.
• Submit each illustration as a separate file.
A detailed guide on electronic artwork is available.
You are urged to visit this site; some excerpts from the detailed information are given here.
Formats
If your electronic artwork is created in a Microsoft Office application (Word, PowerPoint, Excel) then
please supply 'as is' in the native document format.
Regardless of the application used other than Microsoft Office, when your electronic artwork is
finalized, please 'Save as' or convert the images to one of the following formats (note the resolution
requirements for line drawings, halftones, and line/halftone combinations given below):
EPS (or PDF): Vector drawings, embed all used fonts.
TIFF (or JPEG): Color or grayscale photographs (halftones), keep to a minimum of 300 dpi.
TIFF (or JPEG): Bitmapped (pure black & white pixels) line drawings, keep to a minimum of 1000 dpi.
TIFF (or JPEG): Combinations bitmapped line/half-tone (color or grayscale), keep to a minimum of
500 dpi.
Please do not:
• Supply files that are optimized for screen use (e.g., GIF, BMP, PICT, WPG); these typically have a
low number of pixels and limited set of colors;
• Supply files that are too low in resolution;
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• Submit graphics that are disproportionately large for the content.
Color artwork
Please make sure that artwork files are in an acceptable format (TIFF (or JPEG), EPS (or PDF), or
MS Office files) and with the correct resolution. If, together with your accepted article, you submit
usable color figures then Elsevier will ensure, at no additional charge, that these figures will appear
in color online (e.g., ScienceDirect and other sites) regardless of whether or not these illustrations
are reproduced in color in the printed version. For color reproduction in print, you will receive
information regarding the costs from Elsevier after receipt of your accepted article. Please
indicate your preference for color: in print or online only. Further information on the preparation of
electronic artwork.
Figure captions
Ensure that each illustration has a caption. Supply captions separately, not attached to the figure. A
caption should comprise a brief title (not on the figure itself) and a description of the illustration. Keep
text in the illustrations themselves to a minimum but explain all symbols and abbreviations used.
Tables
Please submit tables as editable text and not as images. Tables can be placed either next to the
relevant text in the article, or on separate page(s) at the end. Number tables consecutively in
accordance with their appearance in the text and place any table notes below the table body. Be
sparing in the use of tables and ensure that the data presented in them do not duplicate results
described elsewhere in the article. Please avoid using vertical rules and shading in table cells.
References
Citation in text
Please ensure that every reference cited in the text is also present in the reference list (and vice
versa). Any references cited in the abstract must be given in full. Unpublished results and personal
communications are not recommended in the reference list, but may be mentioned in the text. If these
references are included in the reference list they should follow the standard reference style of the
journal and should include a substitution of the publication date with either 'Unpublished results' or
'Personal communication'. Citation of a reference as 'in press' implies that the item has been accepted
for publication.
Web references
As a minimum, the full URL should be given and the date when the reference was last accessed. Any
further information, if known (DOI, author names, dates, reference to a source publication, etc.),
should also be given. Web references can be listed separately (e.g., after the reference list) under a
different heading if desired, or can be included in the reference list.
Data references
This journal encourages you to cite underlying or relevant datasets in your manuscript by citing them
in your text and including a data reference in your Reference List. Data references should include the
following elements: author name(s), dataset title, data repository, version (where available), year,
and global persistent identifier. Add [dataset] immediately before the reference so we can properly
identify it as a data reference. The [dataset] identifier will not appear in your published article.
References in a special issue
Please ensure that the words 'this issue' are added to any references in the list (and any citations in
the text) to other articles in the same Special Issue.
Reference management software
Most Elsevier journals have their reference template available in many of the most popular reference
management software products. These include all products that support Citation Style Language
styles, such as Mendeley and Zotero, as well as EndNote. Using the word processor plug-ins from
these products, authors only need to select the appropriate journal template when preparing their
article, after which citations and bibliographies will be automatically formatted in the journal's style.
If no template is yet available for this journal, please follow the format of the sample references and
citations as shown in this Guide.
Users of Mendeley Desktop can easily install the reference style for this journal by clicking the following
link:
http://open.mendeley.com/use-citation-style/journal-of-autoimmunity
When preparing your manuscript, you will then be able to select this style using the Mendeley plug-
ins for Microsoft Word or LibreOffice.
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Reference style
Text: Indicate references by number(s) in square brackets in line with the text. The actual authors
can be referred to, but the reference number(s) must always be given.
Example: '..... as demonstrated [3,6]. Barnaby and Jones [8] obtained a different result ....'
List: Number the references (numbers in square brackets) in the list in the order in which they appear
in the text.
Examples:
Reference to a journal publication:
[1] J. van der Geer, J.A.J. Hanraads, R.A. Lupton, The art of writing a scientific article, J. Sci. Commun.
163 (2010) 51–59.
Reference to a book:
[2] W. Strunk Jr., E.B. White, The Elements of Style, fourth ed., Longman, New York, 2000.
Reference to a chapter in an edited book:
[3] G.R. Mettam, L.B. Adams, How to prepare an electronic version of your article, in: B.S. Jones, R.Z.
Smith (Eds.), Introduction to the Electronic Age, E-Publishing Inc., New York, 2009, pp. 281–304.
Reference to a website:
[4] Cancer Research UK, Cancer statistics reports for the UK. http://www.cancerresearchuk.org/
aboutcancer/statistics/cancerstatsreport/, 2003 (accessed 13.03.03).
Reference to a dataset:
[dataset] [5] M. Oguro, S. Imahiro, S. Saito, T. Nakashizuka, Mortality data for Japanese oak wilt
disease and surrounding forest compositions, Mendeley Data, v1, 2015. http://dx.doi.org/10.17632/
xwj98nb39r.1.
Journal abbreviations source
Journal names should be abbreviated according to the List of Title Word Abbreviations.
Video
Elsevier accepts video material and animation sequences to support and enhance your scientific
research. Authors who have video or animation files that they wish to submit with their article are
strongly encouraged to include links to these within the body of the article. This can be done in the
same way as a figure or table by referring to the video or animation content and noting in the body
text where it should be placed. All submitted files should be properly labeled so that they directly
relate to the video file's content. In order to ensure that your video or animation material is directly
usable, please provide the files in one of our recommended file formats with a preferred maximum size
of 150 MB. Video and animation files supplied will be published online in the electronic version of your
article in Elsevier Web products, including ScienceDirect. Please supply 'stills' with your files: you can
choose any frame from the video or animation or make a separate image. These will be used instead
of standard icons and will personalize the link to your video data. For more detailed instructions please
visit our video instruction pages. Note: since video and animation cannot be embedded in the print
version of the journal, please provide text for both the electronic and the print version for the portions
of the article that refer to this content.
Supplementary material
Supplementary material such as applications, images and sound clips, can be published with your
article to enhance it. Submitted supplementary items are published exactly as they are received (Excel
or PowerPoint files will appear as such online). Please submit your material together with the article
and supply a concise, descriptive caption for each supplementary file. If you wish to make changes to
supplementary material during any stage of the process, please make sure to provide an updated file.
Do not annotate any corrections on a previous version. Please switch off the 'Track Changes' option
in Microsoft Office files as these will appear in the published version.
RESEARCH DATA
This journal encourages and enables you to share data that supports your research publication
where appropriate, and enables you to interlink the data with your published articles. Research data
refers to the results of observations or experimentation that validate research findings. To facilitate
reproducibility and data reuse, this journal also encourages you to share your software, code, models,
algorithms, protocols, methods and other useful materials related to the project.
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Below are a number of ways in which you can associate data with your article or make a statement
about the availability of your data when submitting your manuscript. If you are sharing data in one of
these ways, you are encouraged to cite the data in your manuscript and reference list. Please refer to
the "References" section for more information about data citation. For more information on depositing,
sharing and using research data and other relevant research materials, visit the research data page.
Data linking
If you have made your research data available in a data repository, you can link your article directly to
the dataset. Elsevier collaborates with a number of repositories to link articles on ScienceDirect with
relevant repositories, giving readers access to underlying data that give them a better understanding
of the research described.
There are different ways to link your datasets to your article. When available, you can directly link
your dataset to your article by providing the relevant information in the submission system. For more
information, visit the database linking page.
For supported data repositories a repository banner will automatically appear next to your published
article on ScienceDirect.
In addition, you can link to relevant data or entities through identifiers within the text of your
manuscript, using the following format: Database: xxxx (e.g., TAIR: AT1G01020; CCDC: 734053;
PDB: 1XFN).
Data in Brief
You have the option of converting any or all parts of your supplementary or additional raw data into
one or multiple data articles, a new kind of article that houses and describes your data. Data articles
ensure that your data is actively reviewed, curated, formatted, indexed, given a DOI and publicly
available to all upon publication. You are encouraged to submit your article for Data in Brief as an
additional item directly alongside the revised version of your manuscript. If your research article is
accepted, your data article will automatically be transferred over to Data in Brief where it will be
editorially reviewed and published in the open access data journal, Data in Brief. Please note an open
access fee is payable for publication in Data in Brief. Full details can be found on the Data in Brief
website. Please use this template to write your Data in Brief.
AudioSlides
The journal encourages authors to create an AudioSlides presentation with their published article.
AudioSlides are brief, webinar-style presentations that are shown next to the online article on
ScienceDirect. This gives authors the opportunity to summarize their research in their own words
and to help readers understand what the paper is about. More information and examples are
available. Authors of this journal will automatically receive an invitation e-mail to create an AudioSlides
presentation after acceptance of their paper.
Interactive plots
This journal enables you to show an Interactive Plot with your article by simply submitting a data
file. Full instructions.
AFTER ACCEPTANCE
Online proof correction
Corresponding authors will receive an e-mail with a link to our online proofing system, allowing
annotation and correction of proofs online. The environment is similar to MS Word: in addition to
editing text, you can also comment on figures/tables and answer questions from the Copy Editor.
Web-based proofing provides a faster and less error-prone process by allowing you to directly type
your corrections, eliminating the potential introduction of errors.
If preferred, you can still choose to annotate and upload your edits on the PDF version. All instructions
for proofing will be given in the e-mail we send to authors, including alternative methods to the online
version and PDF.
We will do everything possible to get your article published quickly and accurately. Please use this
proof only for checking the typesetting, editing, completeness and correctness of the text, tables and
figures. Significant changes to the article as accepted for publication will only be considered at this
stage with permission from the Editor. It is important to ensure that all corrections are sent back
to us in one communication. Please check carefully before replying, as inclusion of any subsequent
corrections cannot be guaranteed. Proofreading is solely your responsibility.
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Offprints
The corresponding author will, at no cost, receive a customized Share Link providing 50 days free
access to the final published version of the article on ScienceDirect. The Share Link can be used
for sharing the article via any communication channel, including email and social media. For an
extra charge, paper offprints can be ordered via the offprint order form which is sent once the
article is accepted for publication. Both corresponding and co-authors may order offprints at any
time via Elsevier's Webshop. Corresponding authors who have published their article open access do
not receive a Share Link as their final published version of the article is available open access on
ScienceDirect and can be shared through the article DOI link.
AUTHOR INQUIRIES
Visit the Elsevier Support Center to find the answers you need. Here you will find everything from
Frequently Asked Questions to ways to get in touch.
You can also check the status of your submitted article or find out when your accepted article will
be published.
© Copyright 2014 Elsevier | http://www.elsevier.com
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